BDBM352271 5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyran-4-yloxy)nicotinoyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)pyridine-2-sulfonamide::US10654857, Example 1.23::US11098048, Example 1.2::US9802944, Example 1::US9802944, Example 1.01::US9802944, Example 1.02::US9802944, Example 1.03::US9802944, Example 1.04::US9802944, Example 1.05::US9802944, Example 1.06::US9802944, Example 1.07::US9802944, Example 1.08::US9802944, Example 1.09::US9802944, Example 1.10::US9802944, Example 1.11::US9802944, Example 1.12::US9802944, Example 1.13::US9802944, Example 1.14::US9802944, Example 1.15::US9802944, Example 1.16::US9802944, Example 1.17::US9802944, Example 1.18::US9802944, Example 1.19::US9802944, Example 1.2::US9802944, Example 1.21::US9802944, Example 1.22::US9802944, Example 1.23

SMILES NS(=O)(=O)c1ccc(cn1)C(=O)N1C[C@H]2CN(C[C@@H]2C1)C(=O)c1cnc(OC2CCOCC2)c(c1)C1CC1

InChI Key InChIKey=YLIKCNACGAJJCL-PMACEKPBSA-N

Data  50 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 50 hits for monomerid = 352271   

TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  29nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  14nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2), 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  22nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  9nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  8nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  6nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  7nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  7nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  20nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  5nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  8nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  15nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  9nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  3nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  9nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  32nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  6nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  19nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  4nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  7nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  14nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  5nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  14nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  13nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  29nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  17nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  22nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  9nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  8nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  6nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  7nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  7nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  20nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  5nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  8nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  15nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  9nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  3nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  9nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  32nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  6nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  19nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  4nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  7nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  14nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  5nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  14nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  13nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  29nMAssay Description:Assay working solutions were made as follows:Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2), 1 mM MgCl2, 0.01% Triton-X-100, pH 8.0...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAtaxin-2(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM352271(5-((3aS,6aS)-5-(5-Cyclopropyl-6-(tetrahydro-2H-pyr...)
Affinity DataIC50:  17nMAssay Description:ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate). To obtain this MR121...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent